The 2018 National Comprehensive Cancer Network (NCCN) guidelines recommend people in families with BRCA1/2 pathogenic variants, patients with ovarian cancer, and special types of breast cancer (below 45 years old, triple-negative breast cancer, and male breast cancer patients) are required to undergo BRCA1/2 genetic testing [15]. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.